Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

Biodesix, Inc.

Filed: May 19, 2026CIK: 0001439725
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Biodesix held its 2026 annual stockholder meeting on May 19, 2026, where shareholders elected two Class III directors, approved executive compensation on a non-binding basis, and ratified KPMG LLP as the independent auditor for 2026. This is a routine governance event reflecting normal corporate operations and shareholder engagement.

Key Takeaways

Two Class III directors were elected to serve three-year terms through the 2029 annual meeting

Shareholders provided non-binding advisory approval for named executive officer compensation

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 19, 2026
Item5.02
CategoryExecutive Change
CIK0001439725
Accession #0001439725
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board changeregulatory

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings